Khattar Jack A. 4

4 · SUPERNUS PHARMACEUTICALS, INC. · Filed Oct 3, 2025

Form 4

Period: 2025-10-02

DirectorPresident, CEO

Transactions

Exercise/Conversion
Performance Share Units
2025-10-02−19,320→ 0 total
Exercise: $0.00→ Common Stock (19,320 underlying)
Exercise/Conversion
Common Stock
2025-10-02+20,000→ 1,181,233 total
Tax Payment
Common Stock
2025-10-02$46.21/sh−7,796$360,253→ 1,173,437 total
Tax Payment
Common Stock
2025-10-02$46.21/sh−7,529$347,915→ 1,185,228 total
Exercise/Conversion
Common Stock
2025-10-02+19,320→ 1,192,757 total
Exercise/Conversion
Performance Share Unit
2025-10-02−20,000→ 0 total
Exercise: $0.00→ Common Stock (20,000 underlying)

Holdings

Footnotes (5)

[F1]Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 19, 2021.
[F2]Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
[F3]Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2024.
[F4]On February 19, 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on April 30, 2021.
[F5]On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024.

Documents

1 file